{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:15:51Z","timestamp":1770912951960,"version":"3.50.1"},"reference-count":16,"publisher":"Hindawi Limited","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1572,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1742-1241.2011.02668.x","type":"journal-article","created":{"date-parts":[[2011,5,13]],"date-time":"2011-05-13T06:39:33Z","timestamp":1305268773000},"page":"784-789","source":"Crossref","is-referenced-by-count":17,"title":["Effects of telavancin on coagulation test results"],"prefix":"10.1155","volume":"65","author":[{"given":"S. L.","family":"Barriere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W.","family":"Janc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. A.","family":"Macy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. M.","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2011,5,13]]},"reference":[{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7164\/antibiotics.57.326","article-title":"Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424)","volume":"57","author":"Leadbetter","year":"2004","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB2|cit2","first-page":"216","article-title":"Telavancin (Theravance)","volume":"6","author":"Pace","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/13543784.16.3.347","article-title":"Telavancin: a novel lipoglycopeptide for serious gram-positive infections","volume":"16","author":"Laohavaleeson","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2146\/ajhp070080","article-title":"Telavancin: a novel lipoglycopeptide antimicrobial agent","volume":"64","author":"Attwood","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1592\/phco.28.4.458","article-title":"Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections","volume":"28","author":"Leonard","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","article-title":"Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus","volume":"49","author":"Higgins","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/AAC.01710-08","article-title":"Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II","volume":"53","author":"Lunde","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1128\/AAC.49.1.195-201.2005","article-title":"Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects","volume":"49","author":"Shaw","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB9|cit9","volume-title":"Pharmacokinetics (PK) & Safety of a New Antibacterial, TD-6424 (TD), in Healthy Subjects","author":"Barriere","year":"2003"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/429914","article-title":"Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria","volume":"40","author":"Stryjewski","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1128\/AAC.50.3.862-867.2006","article-title":"Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study","volume":"50","author":"Stryjewski","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1538-7836.2007.02679.x","article-title":"Effect of daptomycin on prothrombin time and the requirement for outlier exclusion in International Sensitivity Index calibration of thromboplastin","volume":"5","author":"van den Besselaar","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MBC.0b013e3282f10275","article-title":"Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time\/International Normalized Ratio results","volume":"19","author":"Webster","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB15|cit15","volume-title":"Cubicin\u00ae (daptomycin for injection) [package insert]","year":"2008"},{"key":"10.1111\/j.1742-1241.2011.02668.x-BIB16|cit16","volume-title":"Vibativ\u2122 (telavancin for injection) [package insert]","year":"2009"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2011.02668.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2011.02668.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:08:19Z","timestamp":1643350099000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2011.02668.x"}},"subtitle":["Telavancin and coagulation tests"],"short-title":[],"issued":{"date-parts":[[2011,5,13]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02668.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5,13]]}}}